Paricalcitol

DB00910

small molecule approved investigational

Deskripsi

Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.

Struktur Molekul 2D

Berat 416.6365
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 4 to 6 hours
Volume Distribusi * 30.8 ± 7.5 L [CKD Stage 5-HD] * 34.9 ± 9.5 L [CKD Stage 5-PD] * 23.8 L [healthy subjects]
Klirens (Clearance) * 1.49 +/- 0.60 L/h [chronic kidney disease Stage 5 with hemodialysis] * 1.54 +/- 0.95 L/h [chronic kidney disease Stage 5with peritoneal dialysis]

Absorpsi

Well absorbed

Metabolisme

Metabolized by multiple hepatic and non-hepatic enzymes, including mitochondrial CYP24, as well as CYP3A4 and UGT1A4

Rute Eliminasi

Paricalcitol is excreted primarily by hepatobiliary excretion.

Interaksi Makanan

3 Data
  • 1. Avoid antacids. Avoid taking aluminum-containing antacids chronically with paricalcitol as there is an increased risk of aluminum toxicity.
  • 2. Exercise caution with grapefruit products. Grapefruit inhibits CYP3A4, and paricalcitol metabolism is mediated partially through CYP3A4; therefore, grapefruit may increase paricalcitol serum levels.
  • 3. Take with or without food.

Interaksi Obat

262 Data
Aluminum hydroxide The serum concentration of Aluminum hydroxide can be increased when it is combined with Paricalcitol.
Danazol Danazol may increase the hypercalcemic activities of Paricalcitol.
Sucralfate The serum concentration of Sucralfate can be increased when it is combined with Paricalcitol.
Magnesium sulfate The serum concentration of Magnesium sulfate can be increased when it is combined with Paricalcitol.
Magnesium oxide The serum concentration of Magnesium oxide can be increased when it is combined with Paricalcitol.
Magnesium salicylate The serum concentration of Magnesium salicylate can be increased when it is combined with Paricalcitol.
Magaldrate The serum concentration of Magaldrate can be increased when it is combined with Paricalcitol.
Magnesium hydroxide The serum concentration of Magnesium hydroxide can be increased when it is combined with Paricalcitol.
Magnesium trisilicate The serum concentration of Magnesium trisilicate can be increased when it is combined with Paricalcitol.
Magnesium chloride The serum concentration of Magnesium chloride can be increased when it is combined with Paricalcitol.
Magnesium carbonate The serum concentration of Magnesium carbonate can be increased when it is combined with Paricalcitol.
Talc The serum concentration of Talc can be increased when it is combined with Paricalcitol.
Magnesium citrate The serum concentration of Magnesium citrate can be increased when it is combined with Paricalcitol.
Magnesium silicate The serum concentration of Magnesium silicate can be increased when it is combined with Paricalcitol.
Hydrotalcite The serum concentration of Hydrotalcite can be increased when it is combined with Paricalcitol.
Magnesium aspartate The serum concentration of Magnesium aspartate can be increased when it is combined with Paricalcitol.
Magnesium peroxide The serum concentration of Magnesium peroxide can be increased when it is combined with Paricalcitol.
Magnesium gluconate The serum concentration of Magnesium gluconate can be increased when it is combined with Paricalcitol.
Magnesium orotate The serum concentration of Magnesium orotate can be increased when it is combined with Paricalcitol.
Magnesium The serum concentration of Magnesium can be increased when it is combined with Paricalcitol.
Magnesium levulinate The serum concentration of Magnesium levulinate can be increased when it is combined with Paricalcitol.
Magnesium lactate The serum concentration of Magnesium lactate can be increased when it is combined with Paricalcitol.
Orlistat Orlistat can cause a decrease in the absorption of Paricalcitol resulting in a reduced serum concentration and potentially a decrease in efficacy.
Digoxin The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Paricalcitol is combined with Digoxin.
Acetyldigitoxin The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Paricalcitol is combined with Acetyldigitoxin.
Deslanoside The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Paricalcitol is combined with Deslanoside.
Ouabain The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Paricalcitol is combined with Ouabain.
Oleandrin The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Paricalcitol is combined with Oleandrin.
Cymarin The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Paricalcitol is combined with Cymarin.
Proscillaridin The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Paricalcitol is combined with Proscillaridin.
Metildigoxin The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Paricalcitol is combined with Metildigoxin.
Lanatoside C The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Paricalcitol is combined with Lanatoside C.
Gitoformate The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Paricalcitol is combined with Gitoformate.
Acetyldigoxin The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Paricalcitol is combined with Acetyldigoxin.
Peruvoside The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Paricalcitol is combined with Peruvoside.
Digitoxin The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Paricalcitol is combined with Digitoxin.
Mineral oil Mineral oil can cause a decrease in the absorption of Paricalcitol resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methyclothiazide The risk or severity of hypercalcemia can be increased when Methyclothiazide is combined with Paricalcitol.
Bendroflumethiazide The risk or severity of hypercalcemia can be increased when Bendroflumethiazide is combined with Paricalcitol.
Benzthiazide The risk or severity of hypercalcemia can be increased when Benzthiazide is combined with Paricalcitol.
Cyclothiazide The risk or severity of hypercalcemia can be increased when Cyclothiazide is combined with Paricalcitol.
Hydroflumethiazide The risk or severity of hypercalcemia can be increased when Hydroflumethiazide is combined with Paricalcitol.
Chlorothiazide The risk or severity of hypercalcemia can be increased when Chlorothiazide is combined with Paricalcitol.
Hydrochlorothiazide The risk or severity of hypercalcemia can be increased when Hydrochlorothiazide is combined with Paricalcitol.
Trichlormethiazide The risk or severity of hypercalcemia can be increased when Trichlormethiazide is combined with Paricalcitol.
Polythiazide The risk or severity of hypercalcemia can be increased when Polythiazide is combined with Paricalcitol.
Mebutizide The risk or severity of hypercalcemia can be increased when Mebutizide is combined with Paricalcitol.
Cyclopenthiazide The risk or severity of hypercalcemia can be increased when Cyclopenthiazide is combined with Paricalcitol.
Buthiazide The risk or severity of hypercalcemia can be increased when Buthiazide is combined with Paricalcitol.
Calcitriol The risk or severity of adverse effects can be increased when Calcitriol is combined with Paricalcitol.
Calcifediol The risk or severity of adverse effects can be increased when Calcifediol is combined with Paricalcitol.
Ergocalciferol The risk or severity of adverse effects can be increased when Ergocalciferol is combined with Paricalcitol.
Cholecalciferol The risk or severity of adverse effects can be increased when Cholecalciferol is combined with Paricalcitol.
Dihydrotachysterol The risk or severity of adverse effects can be increased when Paricalcitol is combined with Dihydrotachysterol.
Alfacalcidol The risk or severity of adverse effects can be increased when Paricalcitol is combined with Alfacalcidol.
Seocalcitol The risk or severity of adverse effects can be increased when Paricalcitol is combined with Seocalcitol.
Inecalcitol The risk or severity of adverse effects can be increased when Paricalcitol is combined with Inecalcitol.
Becocalcidiol The risk or severity of adverse effects can be increased when Paricalcitol is combined with Becocalcidiol.
Eldecalcitol The risk or severity of adverse effects can be increased when Paricalcitol is combined with Eldecalcitol.
1alpha,24S-Dihydroxyvitamin D2 The risk or severity of adverse effects can be increased when Paricalcitol is combined with 1alpha,24S-Dihydroxyvitamin D2.
Elocalcitol The risk or severity of adverse effects can be increased when Paricalcitol is combined with Elocalcitol.
Maxacalcitol The risk or severity of adverse effects can be increased when Paricalcitol is combined with Maxacalcitol.
Doxercalciferol The risk or severity of adverse effects can be increased when Paricalcitol is combined with Doxercalciferol.
Vitamin D The risk or severity of adverse effects can be increased when Paricalcitol is combined with Vitamin D.
1alpha-Hydroxyvitamin D5 The risk or severity of adverse effects can be increased when Paricalcitol is combined with 1alpha-Hydroxyvitamin D5.
Previtamin D(3) The risk or severity of adverse effects can be increased when Paricalcitol is combined with Previtamin D(3).
Calcium acetate The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcium acetate.
Calcium glucoheptonate The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcium glucoheptonate.
Calcium chloride The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcium chloride.
Calcium The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcium.
Calcium carbonate The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcium carbonate.
Calcium citrate The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcium citrate.
Calcium gluconate The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcium gluconate.
Calcium Phosphate The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcium Phosphate.
Calcium glubionate anhydrous The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcium glubionate anhydrous.
Calcium lactate The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcium lactate.
Calcium lactate gluconate The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcium lactate gluconate.
Calcium pangamate The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcium pangamate.
Calcium levulinate The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcium levulinate.
Calcium cation The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcium cation.
Calcium polycarbophil The risk or severity of adverse effects can be increased when Paricalcitol is combined with Calcium polycarbophil.
Colestipol The serum concentration of Paricalcitol can be decreased when it is combined with Colestipol.
Sevelamer The serum concentration of Paricalcitol can be decreased when it is combined with Sevelamer.
Colesevelam The serum concentration of Paricalcitol can be decreased when it is combined with Colesevelam.
Cholestyramine The serum concentration of Paricalcitol can be decreased when it is combined with Cholestyramine.
Tixocortol The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Tixocortol.
Fluocortin The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Fluocortin.
Fluperolone The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Fluperolone.
Fluclorolone The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Fluclorolone.
Flunisolide The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Flunisolide.
Beclomethasone dipropionate The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Beclomethasone dipropionate.
Betamethasone The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Betamethasone.
Fluticasone propionate The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Fluticasone propionate.
Fluocinolone acetonide The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Fluocinolone acetonide.
Triamcinolone The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Triamcinolone.
Prednisone The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Prednisone.
Fludrocortisone The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Fludrocortisone.
Hydrocortisone The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Hydrocortisone.
Prednisolone The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Prednisolone.
Methylprednisolone The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Methylprednisolone.

Target Protein

Vitamin D3 receptor VDR

Referensi & Sumber

Synthesis reference: Anchel Schwartz, Alexei Ploutno, Koby Wolfman, "Preparation of paricalcitol." U.S. Patent US20070149489, issued June 28, 2007.

Contoh Produk & Brand

Produk: 87 • International brands: 0
Produk
  • Paricalcitol
    Capsule, liquid filled • 1 ug/1 • Oral • US • Generic • Approved
  • Paricalcitol
    Capsule, liquid filled • 2 ug/1 • Oral • US • Generic • Approved
  • Paricalcitol
    Capsule, liquid filled • 4 ug/1 • Oral • US • Generic • Approved
  • Paricalcitol
    Capsule • 1 mg/1 • Oral • US • Generic • Approved
  • Paricalcitol
    Capsule • 2 mg/1 • Oral • US • Generic • Approved
  • Paricalcitol
    Capsule • 4 mg/1 • Oral • US • Generic • Approved
  • Paricalcitol
    Capsule, gelatin coated • 1 ug/1 • Oral • US • Generic • Approved
  • Paricalcitol
    Capsule, gelatin coated • 2 ug/1 • Oral • US • Generic • Approved
Menampilkan 8 dari 87 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul